52
|
Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy. Transl Res 2016; 175:37-53. [PMID: 27033146 DOI: 10.1016/j.trsl.2016.03.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 03/05/2016] [Accepted: 03/06/2016] [Indexed: 12/21/2022]
Abstract
The scope of this review focuses on recent applications in preclinical and clinical magnetic resonance imaging (MRI) toward accomplishing the goals of early detection and responses to therapy in animal models of Alzheimer's disease (AD). Driven by the outstanding efforts of the Alzheimer's Disease Neuroimaging Initiative (ADNI), a truly invaluable resource, the initial use of MRI in AD imaging has been to assess changes in brain anatomy, specifically assessing brain shrinkage and regional changes in white matter tractography using diffusion tensor imaging. However, advances in MRI have led to multiple efforts toward imaging amyloid beta plaques first without and then with the use of MRI contrast agents. These technological advancements have met with limited success and are not yet appropriate for the clinic. Recent developments in molecular imaging inclusive of high-power liposomal-based MRI contrast agents as well as fluorine 19 ((19)F) MRI and manganese enhanced MRI have begun to propel promising advances toward not only plaque imaging but also using MRI to detect perturbations in subcellular processes occurring within the neuron. This review concludes with a discussion about the necessity for the development of novel preclinical models of AD that better recapitulate human AD for the imaging to truly be meaningful and for substantive progress to be made toward understanding and effectively treating AD. Furthermore, the continued support of outstanding programs such as ADNI as well as the development of novel molecular imaging agents and MRI fast scanning sequences will also be requisite to effectively translate preclinical findings to the clinic.
Collapse
|
53
|
Yu M, Gouw AA, Hillebrand A, Tijms BM, Stam CJ, van Straaten ECW, Pijnenburg YAL. Different functional connectivity and network topology in behavioral variant of frontotemporal dementia and Alzheimer's disease: an EEG study. Neurobiol Aging 2016; 42:150-62. [PMID: 27143432 DOI: 10.1016/j.neurobiolaging.2016.03.018] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 03/11/2016] [Accepted: 03/15/2016] [Indexed: 10/22/2022]
Abstract
We investigated whether the functional connectivity and network topology in 69 Alzheimer's disease (AD), 48 behavioral variant of frontotemporal dementia (bvFTD) patients, and 64 individuals with subjective cognitive decline are different using resting-state electroencephalography recordings. Functional connectivity between all pairs of electroencephalography channels was assessed using the phase lag index (PLI). We subsequently calculated PLI-weighted networks, from which minimum spanning trees (MSTs) were constructed. Finally, we investigated the hierarchical clustering organization of the MSTs. Functional connectivity analysis showed frequency-dependent results: in the delta band, bvFTD showed highest whole-brain PLI; in the theta band, the whole-brain PLI in AD was higher than that in bvFTD; in the alpha band, AD showed lower whole-brain PLI compared with bvFTD and subjective cognitive decline. The MST results indicate that frontal networks appear to be selectively involved in bvFTD against the background of preserved global efficiency, whereas parietal and occipital loss of network organization in AD is accompanied by global efficiency loss. Our findings suggest different pathophysiological mechanisms in these 2 separate neurodegenerative disorders.
Collapse
Affiliation(s)
- Meichen Yu
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Center, Amsterdam, the Netherlands.
| | - Alida A Gouw
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Center, Amsterdam, the Netherlands; Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
| | - Arjan Hillebrand
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Center, Amsterdam, the Netherlands
| | - Betty M Tijms
- Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
| | - Cornelis Jan Stam
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Center, Amsterdam, the Netherlands
| | - Elisabeth C W van Straaten
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Center, Amsterdam, the Netherlands
| | - Yolande A L Pijnenburg
- Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
54
|
Hafkemeijer A, Möller C, Dopper EGP, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YAL, Barkhof F, Scheltens P, van der Grond J, Rombouts SARB. Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Hum Brain Mapp 2015; 37:978-88. [PMID: 26660857 DOI: 10.1002/hbm.23081] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 11/30/2015] [Indexed: 12/24/2022] Open
Abstract
Disease-specific patterns of gray matter atrophy in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD) overlap with distinct structural covariance networks (SCNs) in cognitively healthy controls. This suggests that both types of dementia target specific structural networks. Here, we study SCNs in AD and bvFTD. We used structural magnetic resonance imaging data of 31 AD patients, 24 bvFTD patients, and 30 controls from two centers specialized in dementia. Ten SCNs were defined based on structural covariance of gray matter density using independent component analysis. We studied group differences in SCNs using F-tests, with Bonferroni corrected t-tests, adjusted for age, gender, and study center. Associations with cognitive performance were studied using linear regression analyses. Cross-sectional group differences were found in three SCNs (all P < 0.0025). In bvFTD, we observed decreased anterior cingulate network integrity compared with AD and controls. Patients with AD showed decreased precuneal network integrity compared with bvFTD and controls, and decreased hippocampal network and anterior cingulate network integrity compared with controls. In AD, we found an association between precuneal network integrity and global cognitive performance (P = 0.0043). Our findings show that AD and bvFTD target different SCNs. The comparison of both types of dementia showed decreased precuneal (i.e., default mode) network integrity in AD and decreased anterior cingulate (i.e., salience) network integrity in bvFTD. This confirms the hypothesis that AD and bvFTD have distinct anatomical networks of degeneration and shows that structural covariance gives valuable insights in the understanding of network pathology in dementia.
Collapse
Affiliation(s)
- Anne Hafkemeijer
- Department of Methodology and Statistics, Institute of Psychology, Leiden University, 2300 RB, Leiden, the Netherlands.,Department of Radiology, Leiden University Medical Center, Postzone C2-S, 2300 RC, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2300 RC, Leiden, the Netherlands
| | - Christiane Möller
- Alzheimer Center & Department of Neurology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Center, Postzone C2-S, 2300 RC, Leiden, the Netherlands.,Alzheimer Center & Department of Neurology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands.,Alzheimer Center & Department of Neurology, Erasmus Medical Center, 3000 CA, Rotterdam, the Netherlands
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Center, Postzone C2-S, 2300 RC, Leiden, the Netherlands.,Alzheimer Center & Department of Neurology, Erasmus Medical Center, 3000 CA, Rotterdam, the Netherlands.,Department of Neuropsychology, Erasmus Medical Center, 3000 CA, Rotterdam, the Netherlands
| | | | - John C van Swieten
- Alzheimer Center & Department of Neurology, Erasmus Medical Center, 3000 CA, Rotterdam, the Netherlands.,Department of Clinical Genetics, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Wiesje M van der Flier
- Alzheimer Center & Department of Neurology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands.,Department of Epidemiology and Biostatistics, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Hugo Vrenken
- Department of Radiology and Nuclear Medicine, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands.,Department of Physics and Medical Technology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Yolande A L Pijnenburg
- Alzheimer Center & Department of Neurology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Philip Scheltens
- Alzheimer Center & Department of Neurology, VU University Medical Center, 1007 MB, Amsterdam, the Netherlands
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Center, Postzone C2-S, 2300 RC, Leiden, the Netherlands
| | - Serge A R B Rombouts
- Department of Methodology and Statistics, Institute of Psychology, Leiden University, 2300 RB, Leiden, the Netherlands.,Department of Radiology, Leiden University Medical Center, Postzone C2-S, 2300 RC, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2300 RC, Leiden, the Netherlands
| |
Collapse
|